TY - JOUR
T1 - The Hypersomnia Severity Index
T2 - reliability, construct, and criterion validity in a clinical sample of patients with sleep disorders
AU - Fernandez-Mendoza, Julio
AU - Puzino, Kristina
AU - Amatrudo, Gregory
AU - Bourchtein, Elizaveta
AU - Calhoun, Susan L.
AU - Plante, David T.
AU - Kaplan, Kate
N1 - Funding Information:
All authors have seen and approved the final manuscript. Work for this study was performed at the Sleep Research and Treatment Center of Penn State Health Milton S. Hershey Medical Center, Hershey, PA. Dr. Fernandez-Mendoza has received unrelated research support from the National Heart, Lung, and Blood Institute (R01HL136587), the National Institute of Mental Health (R01MH118308), the American Heart Association (14SDG19830018), the Patient-Centered Outcome Research Institute (subcontract with grant number CER2018C213262), and Pfizer Central Research (NCT03665454). Dr. Plante has received unrelated research support from the American Sleep Medicine Foundation, the National Institutes of Health, the University of Illinois at Chicago Occupational and Environmental Health and Safety Education and Research Center (funded by the National Institute for Occupational Safety and Health), and the Madison Educational Partnership. Dr. Plante has served as a consultant for Teva Pharmaceuticals Australia, a consultant for Harmony Biosciences, and as a consultant/medical advisory board member for Jazz Pharmaceuticals. All other authors report no conflicts of interest.
Funding Information:
The authors thank the sleep technicians and staff of the Sleep Research and Treatment Center for their effort and support with this project. All authors have seen and approved the final manuscript. Work for this study was performed at the Sleep Research and Treatment Center of Penn State Health Milton S. Hershey Medical Center, Hershey, PA. Dr. Fernandez-Mendoza has received unrelated research support from the National Heart, Lung, and Blood Institute (R01HL136587), the National Institute of Mental Health (R01MH118308), the American Heart Association (14SDG19830018), the Patient-Centered Outcome Research Institute (subcontract with grant number CER2018C213262), and Pfizer Central Research (NCT03665454). Dr. Plante has received unrelated research support from the American Sleep Medicine Foundation, the National Institutes of Health, the University of Illinois at Chicago Occupational and Environmental Health and Safety Education and Research Center (funded by the National Institute for Occupational Safety and Health), and the Madison Educational Partnership. Dr. Plante has served as a consultant for Teva Pharmaceuticals Australia, a consultant for Harmony Biosciences, and as a consultant/medical advisory board member for Jazz Pharmaceuticals. All other authors report no conflicts of interest.
Publisher Copyright:
Copyright 2022 American Academy of Sleep Medicine. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - Study Objectives: The Hypersomnia Severity Index (HSI) was designed to assess the severity and impairment of hypersomnolence and has been validated in persons with psychiatric disorders. Little is known about its psychometric properties in clinical samples of patients with sleep disorders. Methods: One hundred fifty-eight patients (aged 44.1 ± 16.4 years, 29.1% male, 19.6% racial/ethnic minority) evaluated at the Behavioral Sleep Medicine program of the Penn State Health Sleep Research and Treatment Center completed the HSI and other patient-reported outcomes. We examined the HSI’s reliability and factorial, construct, and criterion validity. Results: The HSI showed satisfactory internal consistency (α = 0.79). A 2-factor structure, reflecting symptoms (HSI-S) and impairment, explained 56.2% of the variance. Convergent validity with the Epworth Sleepiness Scale was optimal (r = .65) but greater for HSI-S (r = .69) than for impairment (r = .39). Divergent validity was optimal for HSI-S against unrelated measures of sleep effort, reactivity, and incompatible behaviors (r ≤ .02). Construct validity showed higher scores in patients with central disorders of hypersomnolence and lower scores in patients with chronic insomnia disorder compared to those with other sleep disorders; however, these divergent scores were primarily driven by HSI-S rather than impairment. Criterion validity showed that an HSI-S cutoff score ≥ 8 provided the best balance in sensitivity/ specificity (0.82/0.78) to identify central disorders of hypersomnolence (area under the curve, 0.85). Conclusions: The HSI shows satisfactory indices of reliability and validity in a clinical patient sample. Its construct and criterion validity are supported by its divergent association with other patient-reported outcomes and central disorders of hypersomnolence vs chronic insomnia disorder diagnoses and the adequate sensitivity/ specificity of its HSI-S cutoff score to reliably identify central disorders of hypersomnolence.
AB - Study Objectives: The Hypersomnia Severity Index (HSI) was designed to assess the severity and impairment of hypersomnolence and has been validated in persons with psychiatric disorders. Little is known about its psychometric properties in clinical samples of patients with sleep disorders. Methods: One hundred fifty-eight patients (aged 44.1 ± 16.4 years, 29.1% male, 19.6% racial/ethnic minority) evaluated at the Behavioral Sleep Medicine program of the Penn State Health Sleep Research and Treatment Center completed the HSI and other patient-reported outcomes. We examined the HSI’s reliability and factorial, construct, and criterion validity. Results: The HSI showed satisfactory internal consistency (α = 0.79). A 2-factor structure, reflecting symptoms (HSI-S) and impairment, explained 56.2% of the variance. Convergent validity with the Epworth Sleepiness Scale was optimal (r = .65) but greater for HSI-S (r = .69) than for impairment (r = .39). Divergent validity was optimal for HSI-S against unrelated measures of sleep effort, reactivity, and incompatible behaviors (r ≤ .02). Construct validity showed higher scores in patients with central disorders of hypersomnolence and lower scores in patients with chronic insomnia disorder compared to those with other sleep disorders; however, these divergent scores were primarily driven by HSI-S rather than impairment. Criterion validity showed that an HSI-S cutoff score ≥ 8 provided the best balance in sensitivity/ specificity (0.82/0.78) to identify central disorders of hypersomnolence (area under the curve, 0.85). Conclusions: The HSI shows satisfactory indices of reliability and validity in a clinical patient sample. Its construct and criterion validity are supported by its divergent association with other patient-reported outcomes and central disorders of hypersomnolence vs chronic insomnia disorder diagnoses and the adequate sensitivity/ specificity of its HSI-S cutoff score to reliably identify central disorders of hypersomnolence.
UR - http://www.scopus.com/inward/record.url?scp=85121958066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121958066&partnerID=8YFLogxK
U2 - 10.5664/jcsm.9426
DO - 10.5664/jcsm.9426
M3 - Article
C2 - 34032202
AN - SCOPUS:85121958066
SN - 1550-9389
VL - 17
SP - 2249
EP - 2256
JO - Journal of Clinical Sleep Medicine
JF - Journal of Clinical Sleep Medicine
IS - 11
ER -